More recently, the 2021 ESC Guidelines on cardiovascular disease prevention confirmed this indication, suggesting GLP1-RAs in individuals with T2D and atherosclerotic cardiovascular disease (ASCVD) to reduce CV and cardiorenal outcomes (class of recommendation I, level of evidence A) [14]. This evidence concerns the gene GCG and cardiovascular disorder.